Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 28

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 28
---
ran Iohan (new member of the Board of Directors) and Ms. Liora Oren (new member of the Board of Directors). For a short biography of the newly elected members of the Board of Directors, see Proposal 9 on the agenda. Proposal:The Board of Directors proposes that the following persons shall be elected individually as members of the Compensation, Nomination and Governance Committee for a term of office until the conclusion of the next ordinary Annual Shareholders Meeting: Mr.Olivier Samuel Mr.Eran Iohan Ms. Liora Oren 11.Advisory Vote: Composition of the New Senior Management following the Merger Explanation:In connection with the Merger, the Company’s senior management is intended to be newly constituted. The Board of Directors believes that the newly proposed members of the senior management are well suited to the position. Swiss law does not require the election of the senior management by the shareholders’ meeting. Nevertheless, the Board of Directors proposes that the extraordinary shareholders meeting approves, on an advisory basis, the election of the following persons to the senior management: Mr. Ronen Twito (Executive Chairman and Chief Executive Officer): for a short biography, see above. Prof. Michel Revel, MD, PhD (Chief Scientific Officer): for a short biography, see above. Dr. Kfir Molakandov, PhD (Vice President Research and Development):Dr. Kfir Molakandov has served as Vice President and Head of Research and Development at Kadimastem since January 2018, and he was previously a researcher at Kadimastem from January 2011 until December 2017. He received his B.A, M.Sc. in Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from Tel Aviv University, Israel. Prof. Ariel Revel, MD (Director of Medical Affairs):Professor Ariel Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served as a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a Professor of Medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009, and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April 2017 until April 2024, he served at the Assaf Harofeh Medical Center. On April 2017 until April 2021